August 2017

4 APAC / August 2017 NEWS , Licensing Agreement to Develop and Commercialise Novel Cancer Therapy Niraparib in Japan TESARO, Inc. and Takeda Pharmaceutical Company Limited on July 27 announced an exclusive licensing agreement for the commercialisation and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor.